Welcome to CSNpharm! For Research Use Only!

ERR

ERR

Cat. No. Product Name CAS No. Information
CSN25739 ZK 164015 177583-70-9 ZK 164015 is an antagonist of estrogen receptor. It inhibits 17β-estradiol stimulation of luciferase activity with IC50 of 0.025 μM.
CSN23201 Y134 849662-80-2 Selective estrogen receptor modulator (SERM), selective for ERα
CSN28481 PROTAC ERRα Degrader-2 2306388-85-0 PROTAC ERRα Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader.
CSN28500 PROTAC ERRα Degrader-1 2306388-84-9 PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader.
CSN28497 PROTAC ER Degrader-4 2361114-15-8 PROTAC ER Degrader-4 is a PROATC estrogen receptor (ER) degrader, binding to ER with an IC50 of 0.8 nM. PROTAC ER Degrader-4 induces ER degradation in MCF-7 cells with an IC50 of 0.3 nM.
CSN26190 Propyl pyrazole triol 263717-53-9 Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%). PPT also exerts anti-diabetic effects in mouse models.
CSN19099 Resmetirom 920509-32-6 MGL-3196 is a selective thyroid hormone receptor agonist with EC50s of 0.21 and 3.74 M for TR and TR respectively.
CSN24502 MB-07811 (VK-2809) 852948-13-1 MB-07811 is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist with cholesteroland triglycerides lowering activity.
CSN12274 Liquiritigenin 578-86-9 Liquiritigenin is an estrogenic compound which fuctions as a selective agonist of the estrogen receptor ER and an partial agonist of ER. It also has choleretic effect. Liquiritigenin is a flavanone extracted from glycyrrhiza uralensis with antitumour action.
CSN22924 H3B-5942 2052128-15-9 H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with Kis of 1 nM and 0.41 nM, respectively.
CSN26546 GSK5182 877387-37-6 GSK5182 is a specific inverse agonist for estrogen-related receptor γ.
CSN26648 Giredestrant tartrate 2407529-33-1 Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity[1].
CSN26647 Giredestrant 1953133-47-5 Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity[1].
CSN19421 Genistin   529-59-9 Genistin is a isoflavone which has a role in blocking cell cycle and inducing apoptosis. It is also a modulator of estrogen receptor. Genistin can be isolated from the seeds of glycine max (L.) merr. and used as negative control of genistein.
CSN21091 GDC-0927 1642297-01-5 GDC-0927, also known as SRN-927, is a next-generation oral SERD, appears to have greater potential than GDC-0810 to be a best-in-class SERD molecule.
CSN24207 GDC-0927 HCl 1642297-02-6 GDC-0927 is a next-generation oral SERD.
CSN25302 Estrogen receptor modulator 1 63676-22-2 Estrogen receptor modulator 1 is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. It has been found to be both estrogenic and antiproliferative in ER-positive endocrine-resistant breast cancer cell lines that overexpress protein kinase C alpha (PKCα).
CSN24698 PROTAC ERRα ligand 2 2306388-57-6 ERRα degrader ligand 4a block the protein-protein interaction of ERRα with PGC-1α coactivator with IC50 value of 5.67nM in a TR-FRET assay.
CSN27511 ERRα antagonist-1 1072145-33-5 ERRα antagonist-1 (Compound A) is a selective and high affinity estrogen-related receptor α (ERRα) antagonist. ERRα antagonist-1 inhibits interaction of ERRα with Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) and PGC-1β, the IC50 values are 170 nM and 180 nM, respectively. ERRα antagonist-1 does not inhibit the interaction of either ERRβ or ERRγ with PGC-1α and PGC-1β coactivator, and also does not inhibit interaction of ERα or ERβ with PGC-1α or SRC-1.
CSN12284 (-)-(S)-Equol   531-95-3 Equol, a non-steroidal estrogen, is a selective agonist of ER. It is produced from the metabolism of the isoflavonoid phytoestrogen daidzen by human intestinal microflora.
CSN12352 Calycosin 20575-57-9 Calycosin, a phytoestrogen, is a partial agonist of ER and a calcium channel blocker. It also shows prevention of reperfusion injury. Calycosin can be isolated and purified from the herb of Astragalus membranaceus Bge. var. mongholicus with anti-oxidative activity.
CSN21522 Bifluranol 34633-34-6 Bifluranol is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol that has been used as an antiandrogen in the United Kingdom in the treatment of benign prostatic hyperplasia.
CSN27628 Camizestrant 2222844-89-3 AZD-9833 is a potent and orally active estrogen receptor (ER) antagonist. AZD-9833 is used for the study of ER+ HER2-advanced breast cancer[1].
CSN28406 ARV-471 2614417-52-4 ARV-471 is the first-clinical-entered ERα PROTAC degrader with DC50 of ~1nM. It degrades clinically-relevant ESR1 variants (Y537S and D538G) and inhibits growth of cell lines expressing those variants.
CSN32897 Amcenestrant 2114339-57-8 Amcenestrant is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD).
CSN26189 (E/Z)-4-Hydroxytamoxifen   68392-35-8 Afimoxifene is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. Afimoxifene is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes.
CSN21921 (R)-Equol 221054-79-1 (R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively.
CSN38973 GW7604 195611-82-6
<< PREV 1 2 3 4 NEXT >>